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Postapproval trials versus patient registries: comparability of 
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Postapproval trials and patient registries have their pros 
and cons in the generation of postapproval data. No 
direct comparison between clinical outcomes of these 
data sources currently exists for advanced melanoma 
patients. We aimed to investigate whether a patient 
registry can complement or even replace postapproval 
trials. Postapproval single-arm clinical trial data from the 
Medicines Evaluation Board and real-world data from 
the Dutch Melanoma Treatment Registry were used. 
The study population consisted of advanced melanoma 
patients with brain metastases treated with targeted 
therapies (BRAF- or BRAF-MEK inhibitors) in the first 
line. A Cox hazard regression model and a propensity 
score matching (PSM) model were used to compare the 
two patient populations. Compared to patients treated in 
postapproval trials (n = 467), real-world patients (n = 602) 
had significantly higher age, higher ECOG performance 
status, more often ≥3 organ involvement and more 
symptomatic brain metastases. Lactate dehydrogenase 
levels were similar between both groups. The unadjusted 
median overall survival (mOS) in postapproval clinical 
trial patients was 8.7 (95% CI, 8.1–10.4) months compared 
to 7.2 (95% CI, 6.5–7.7) months (P < 0.01) in real-world 
patients. With the Cox hazard regression model, survival 
was adjusted for prognostic factors, which led to a 
statistically insignificant difference in mOS for trial and 
real-world patients of 8.7 (95% CI, 7.9–10.4) months 
compared to 7.3 (95% CI, 6.3–7.9) months, respectively. 
The PSM model resulted in 310 matched patients 
with similar survival (P = 0.9). Clinical outcomes of 
both data sources were similar. Registries could be a 
complementary data source to postapproval clinical trials 
to establish information on clinical outcomes in specific 
subpopulations. Melanoma Res 31: 58–66 Copyright © 
2020 The Author(s). Published by Wolters Kluwer Health, 
Inc.
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Introduction
For certain subgroups of patients, long-term benefits, 
safety and efficacy of novel drugs or drug combinations 
may not be proven at the time of market access. To 
obtain additional evidence, specific patient populations 
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are investigated in postapproval clinical trials. These 
trials use strict inclusion and exclusion criteria, cre-
ating efficacy and safety data in a relatively homoge-
nous patient population [1]. A new method to collect 
postapproval clinical data, incorporating patients in a 
‘real-world’ setting, is the use of drug-, patient- or dis-
ease-specific registries. To guide the use of these reg-
istries in the medicine evaluation by regulators, the 
European Medicines Agency (EMA) launched a ‘Patient 
Registries Initiative’ in 2015 [2]. Several programs and 
projects were also initiated by the US Food and Drug 
Administration to use real-world evidence in regulatory 
decision making [3].
Postapproval clinical trials and registries have their pros 
and cons. Trials can be time-consuming and expensive 
and are not always representative of the real-world 
population. Trials include a homogeneous study cohort 
consisting of patients with similar characteristics and 
treatments, resulting in high internal validity and more 
readily interpretable results. Assessment of safety and 
disease progression in trial patients are structured and 
similar for all patients. In contrast, real-world patients 
have heterogeneous patient and disease characteris-
tics and are not always treated identically. Hence, effi-
cacy and safety results are not obtained, assessed and 
reported in the same way. Data on patients in registries 
can be an advantage in answering questions related 
to long-term outcomes and the safety of medicines, 
which cannot be investigated in postapproval clinical 
trials with a short follow-up. Furthermore, large reg-
istries, covering all patients with a specific disease or 
disease stage, provide information on higher numbers 
of specific patient populations, compared to oftentimes 
limited numbers of patients in postapproval clinical 
trials. These advantages of registries may be valuable 
to assess the benefit of cancer therapies. The need for 
postapproval effectiveness data is becoming increas-
ingly more important since benefit-risk assessments of 
new medicines have been based on smaller, single-arm 
trials. Postapproval data can be used for additional 
insights of these medicines and to confirm expected 
benefits.
Multiple targeted therapies and immunotherapies 
received marketing authorization, leading to increased 
treatment options for stages III and IV (advanced) mel-
anoma patients [4]. Phase III trials, including these 
drugs, showed significant improvements in the survival 
of these patients [5–9]. The approved indication of drugs 
is sometimes broader than the strictly selected patient 
population investigated in trials. For example, during 
the time of approval of the BRAF-inhibitors, regulators 
requested more data of the applicant on the efficacy of 
the BRAF-inhibitors in advanced melanoma patients 
with brain metastases. Patients with brain metastases, 
whether asymptomatic or symptomatic, were excluded 
from pivotal trials, but the approved indication included 
these patients [10–12]. Such patients belong to a sub-
group of significant interest as melanoma is the third 
most common cancer with metastases to the brain [13]. 
Postapproval trials in advanced melanoma patients with 
brain metastases were conducted to answer questions 
from regulators on the efficacy of targeted therapies in 
this particular subgroup.
Data on advanced melanoma patients have also been 
collected in the nationwide Dutch Melanoma Treatment 
Registry (DMTR). This disease-specific registry was 
established in 2013 to assure the safety and quality of 
advanced melanoma care in the Netherlands by pro-
viding insight into the outcomes of daily clinical prac-
tice [14]. The DMTR includes all advanced melanoma 
patients and provides information about patient, tumor 
and treatment characteristics as well as outcomes. The 
DMTR is, thus, a potential source for postapproval data 
collection.
Earlier research has shown that patient registries are a 
less used resource for regulatory authorities in the assess-
ments of drugs [15]. This may be because, although 
postapproval clinical trials and patient registries can both 
be used for postapproval data collection, no direct com-
parison of patient characteristics and survival in these 
two postapproval data sources yet exists. This study 
uses advanced melanoma patient data to compare these 
two data sources for postapproval data collection and to 




The study population consisted of advanced melanoma 
patients (≥18 years) with symptomatic or asymptomatic 
brain metastases treated with first-line targeted therapy, 
including BRAF-MEK combination and BRAF mono-
therapy. We constructed two treatment groups: patients 
treated in postapproval clinical trials (trial patients) and 
patients treated in daily clinical practice (real-world 
patients). Real-world patients were treated in the 14 des-
ignated melanoma centers in the Netherlands between 
2012 and 2019.
Data sources
The database of the Medicines Evaluation Board was 
used, including postapproval clinical trials. These data 
were supplied by applicants to the EMA after market 
authorization. The second data source, the DMTR, is 
a nationwide prospective patient registry, including all 
advanced melanoma patients diagnosed since 2012 [14].
Pooling of trials
Patient- and tumor baseline characteristics of patients 
treated in single-arm postapproval trials were analyzed 
with a chi-square test to find potential differences 
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between these trials. Analyzed baseline characteristics 
were age, gender, Eastern Cooperative Oncology Group 
Performance score (ECOG PS), serum lactate dehydro-
genase (LDH), prior brain radiation, previous brain sur-
gery, number of organ sites with metastases, symptomatic 
or asymptomatic brain metastases, type of targeted ther-
apy and year of treatment. These baseline characteristics 
have been previously described as predictive factors for 
clinical outcomes of advanced melanoma patients [16]. 
Overall survival (OS) of the trials was adjusted for prog-
nostic factors by a Cox proportional hazard regression 
model. After adjustment for baseline characteristics, the 
hazard ratios for survival did not differ between the trials. 
The trials could, therefore, be aggregated as one popula-
tion. The total number of trial patients was compared to 
real-world patients.
Primary outcome
The primary outcome in the postapproval clinical tri-
als was the (intracranial) response rate. The secondary 
outcome was OS meeting the requested effectiveness 
of advanced melanoma patients with brain metastases. 
Because the intracranial response rate is not registered 
in the DMTR, we used the Kaplan–Meier method to 
analyze median OS (mOS) as the primary outcome with 
corresponding 95% confidence intervals (CI).
Statistical analysis
Patient characteristics of trial and real-world patients 
were analyzed using descriptive statistics. OS was cal-
culated from the date of start systemic therapy until the 
date of death from any cause or date of the last contact. 
Patients who did not reach the endpoint were censored at 
last contact. Median follow-up time was calculated using 
the reverse Kaplan–Meier method [17].
Two statistical models were used to compare trial 
patients with real-world patients. The first was a mul-
tivariable Cox hazard regression model. The propor-
tionality assumption of the variables in the Cox model 
was investigated using scaled Schoenfeld residuals. OS 
was adjusted for baseline characteristics using the Cox 
model. The Kaplan–Meier estimates of the two patient 
populations were compared with a log-rank test. The 
second model used to compare the two data sources 
was propensity score matching (PSM). This model gives 
a propensity score to each individual based on base-
line patient, tumor and treatment characteristics. The 
propensity scores of patients from the trial group are 
matched to individuals from the real-world data group. 
This model only focuses on matched patients, meaning 
that these patients were equal to each other in terms of 
patient, tumor and treatment characteristics. Matching 
was performed on age, gender, ECOG PS LDH, num-
ber of organ sites, type of therapy, year of treatment and 
symptomatic or asymptomatic brain metastases. Because 
matched groups are not independent in this model, the 
two groups were compared with the stratified log-rank 
test.
Data handling and statistical analyses were performed 
using the R software system for statistical computing 




Four single-arm postapproval clinical trials in patients 
with advanced melanoma and brain metastases were 
pooled, resulting in a dataset of  467 patients. All these 
trial patients were treated with first-line BRAF-MEK 
combination or BRAF monotherapy. Between 2012 and 
2019, 1199 patients with advanced melanoma and brain 
metastases were registered in the DMTR (Fig. 1), with 
602 (50%) patients treated with first-line targeted therapy. 
The main differences in patient- and tumor characteris-
tics between trial and real-world patients treated with 
first-line targeted therapy are shown in Table  1. Real-
world patients had significantly poorer characteristics: 
higher age, higher ECOG PS, more organ site involve-
ment and more often symptomatic brain metastases. The 
unadjusted mOS of real-world patients was 7.2 (95% CI, 
6.5–7.7) months and significantly lower (P < 0.01) than the 
mOS of postapproval clinical trial patients, which was 8.7 
(95% CI, 8.1–10.4) months (Fig. 2). After having adjusted 
for baseline characteristics, median survival times in the 
two groups were similar.
Cox hazard regression model
A multivariable Cox regression hazard model, comparing 
real-world patients to those treated in the postapproval 
clinical trials, showed a hazard ratio on survival of 1.19 
(95% CI, 0.93–1.51; P = 0.165) for real-world patients. 
This hazard ratio is adjusted for the prognostic fac-
tors shown in Fig. 3. In this Cox model, age >70 years, 
ECOG PS ≥2, symptomatic brain metastases, metastases 
in ≥3 organ sites and elevated LDH were significantly 
negatively associated with survival. As compared to 
BRAF monotherapy, combination therapy with BRAF-
MEK was significantly positively associated with sur-
vival (hazard ratio, 0.67; 95% CI,0.54–0.84; P < 0.001). 
Another factor that improved survival was prior brain 
surgery, compared to patients who did not receive brain 
surgery, with an hazard ratio of 0.68 (95% CI, 0.53–0.87; 
P = 0.002). Survival was also influenced by the start year 
of targeted therapy, with patients treated in more recent 
years having an improved survival (Fig.  3). The OS of 
the two subgroups was adjusted for prognostic factors, 
which led to a statistically insignificant difference in 
mOS of, respectively, 8.7 (95% CI, 7.9–10.4) compared 
to 7.3 (95% CI, 6.3–7.9) months for trial and real-world 
patients.
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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Propensity score matching model
The total patient population consisted of 602 real-world 
patients and 467 trial patients. To perform PSM, 76 
real-world patients with missing values were excluded 
from the model before matching. In total 993 patients 
remained for matching and 310 (30.6%) patients were 
matched, resulting in 155 pairs of patients from the real-
world and trial population. After matching, none of the 
prognostic factors differed between the two data sources. 
The stratified log-rank test resulted in similar survival 
(P = 0.9) of real-world and trial patients (Fig.  4). The 
other 683 patients could not be matched with an indi-
vidual from the other data source, because of differences 
in ECOG PS and the presence of symptomatic versus 
asymptomatic brain metastases. Only a limited number of 
patients with symptomatic brain metastases and ECOG 
PS ≥2 were included in the trials (Table 1).
Discussion
Comparison of the outcomes of the data sources
In this study, we compared outcomes of postapproval 
clinical trials with data from a disease-specific registry to 
explore whether a registry can complement postapproval 
clinical trials after market authorization of medicines. 
The absolute difference in the unadjusted median OS 
of the two groups was minimal (1.5 months), which can 
be explained by the fact that these patients with brain 
metastases are included in postapproval clinical trials, 
but would have been excluded from the phase-III trials. 
Therefore, these patients included in the postapproval 
Fig. 1
Flowchart of patient population and the two statistical models used.
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clinical trials are more similar to real-world patients than 
advanced melanoma patients included in phase-III trials. 
However, postapproval trial patients did not completely 
represent the real-world population. There were still 
major differences in patient and tumor characteristics 
between the two groups. Real-world patients had more 
often symptomatic brain metastases (69%) compared to 
trial patients (9%). Differences were also found in age, 
ECOG PS, organ site involvement and whether prior 
brain surgery was performed. Patients receiving brain 
surgery have relatively more favorable characteristics. 
These differences resulted in seemingly better survival 
among clinical trial patients, which is in general, the case 
for other conditions as well. After correction for baseline 
characteristics, the clinical outcomes of the two patient 
populations did not differ. We can, therefore, argue that 
no other prognostic factors (i.e. stricter treatment sched-
ules and controls) contribute to the differences in sur-
vival between these patients treated in postapproval 
trials and real-world patients registered in the DMTR. 
The survival of real-world patients who were matched to 
trial patients was similar.
Other outcomes for measurement
The primary outcome in the postapproval trials was 
intracranial response. This outcome has not been regis-
tered in the DMTR and, therefore, the OS of the two 
patient groups was compared. Survival is an objective 
outcome that is well documented in both sources.
Safety or quality-of-life of advanced melanoma patients 
with brain metastases were not investigated and com-
pared in this study because registration of adverse events 
in postapproval trials and the DMTR are different. 
Individual data on the grade of toxicity in the postap-
proval trials were lacking, and because only grade 3 and 
4 toxicities are registered in the DMTR, we could not 
compare safety. Furthermore, the patient-reported out-
come measurements questionnaires are filled out by 
a relatively low number of patients in the DMTR and 
were not used in these postapproval trials. In the future, 
safety and quality-of-life could also be measured in reg-
istries using similar methods as in trials, including grade 
1 and 2 toxicities and more specific data on the date of 
toxicity and the consequences of toxicity (discontinua-
tion and hospitalization). Registries can then be used for 
safety concerns or measurements in postapproval data 
collection.
Requirements of the data sources
Postapproval clinical trials and registries are both used by 
regulators in the medicine’s evaluation. However, earlier 
research showed that registry data are more often used 
by regulators for (long-term) safety of medicines and less 
used for effectiveness [18]. In only seven of the 73 (9.6%) 
registries, that were used in the risk management plan 
of medicines, the primary goal was real-world safety and 
effectiveness [18]. Real-world information on medicines 
is also used by other stakeholders, such as health tech-
nology assessment (HTA) organizations, payers and man-
ufacturers [19].
Both data sources need to meet several requirements 
to lead to valuable and trustworthy data for regulatory 
assessments. In both data sources, patient numbers and 
the length of follow-up should be of sufficient duration to 
measure clinical outcomes. The proportion of excluded 
patients in postapproval trials should be minimalized to 
be representative of actual clinical care [1]. The postap-
proval trials used in this study were single-arm trials and 
therefore lacked a comparator. The inclusion and exclu-
sion criteria used, except for the presence of brain metas-
tases, were similar to those used in the pivotal clinical 
trials, leading to an underrepresentation of the real-world 
population.
To reduce bias, registries need to be validated, complete 
and consistent. This requires consistency in the regis-
tration of variables by hospitals and the measurement 
of clinical outcomes. Important factors supporting the 
Table 1 Baseline characteristics of targeted therapy treated 
advanced melanoma patients with brain metastases in post 
approval clinical trials and in real-world
Baseline Clinical trials Real-world P value
Patients, n 467 602  
Gender, n (%)   0.069
 Male 295 (63.2) 346 (57.5)  
 Female 172 (36.8) 256 (42.5)  
Age [median (range)] 53 (19–87) 58 (18–92) <0.001
ECOG PS, n (%)   <0.001
 ≤1 459 (98.3) 401 (66.6)  
 ≥2 8 (1.7) 129 (21.4)  
 Unknown 0 72 (12.0)  
LDH, n (%)   <0.001
 Not determined 0 21 (3.5)  
 Normal 212 (45.4) 293 (48.8)  
 1-2 × ULN 148 (31.7) 174 (29.0)  
 >2 × ULN 107 (22.9) 112 (18.7)  
Distant metastases, n (%)   <0.001
 <3 organ sites 196 (42.0) 172 (28.6)  
 ≥3 organ sites 271 (58.0) 430 (71.4)  
Type of therapy, n (%)   <0.001
 BRAFi mono 342 (73.2) 262 (43.5)  
 BRAFi/MEKi combi 125 (26.8) 340 (56.5)  
Brain metastases, n (%)   <0.001
 Asymptomatic 426 (91.2) 189 (31.5)  
 Symptomatic 41 (8.8) 411 (68.5)  
Brain surgery, n (%)   <0.001
 No 364 (77.9) 560 (93.0)  
 Yes 103 (22.1) 42 (7.0)  
Brain radiation, n (%)   <0.001
 No 318 (68.1) 336 (55.8)  
 Yes 149 (31.9) 265 (44)  
 Unknown 0 1 (0.2)  
Start target therapy year, n (%)   <0.001
 2010–2011 219 (46.9) 0  
 2012–2013–2014 188 (40.3) 185 (30.7)  
 2015–2016 60 (12.8) 168 (27.9)  
 2017–2018–2019 0 249 (41.4)  
Distant metastases – number of organ sites with metastases.
ECOG PS, Eastern Cooperative Oncology Group Performance score; LDH, lac-
tate dehydrogenase.
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consistency, allowing the use of registries in medicine 
evaluation by regulators, would include, for example, 
the use of common datasets and coding terminologies, 
complete data collection, and quality assurance and 
consistent governance [15,20]. The registry used in this 
study, the DMTR, is a validated, nationwide patient 
registry with limited missing patients and data. DMTR 
data quality control is performed by medical oncologists 
and independent reviewers. Data managers are trained 
to register data accurately. They follow patients until 
death, and electronic patient records are checked every 3 
months. DMTR data are also accessible and shared with 
multiple stakeholders [14]. At the same time, because an 
adequate (untreated) comparator is lacking, registry data 
are not sufficient to determine the benefit/risk balance 
of novel drugs. Furthermore, registry data reflect the less 
tightly controlled and registered dosing schedules and 
medication adherence of real-world practice, possibly 
leading to variation in clinical outcomes.
Deciding which data source to use
The comparison of data sources leads to the question of 
which data source regulators should request and allow 
when postapproval data is needed. This choice highly 
depends on three main aspects. First, it depends on the 
questions that regulators have when they are deciding on 
marketing approval. When researching clinical benefit or 
treatment strategies of novel drugs, trials are preferred. 
Registries can be of major value to indicate outcomes of 
specific populations, such as mucosal or uveal melanoma 
patients and ineligible patients [21]. Data from registries 
can also be used to measure outcomes of practical treat-
ment schedules and strategies, such as treatment steps 
and treatment duration. These results from registries 
Fig. 2
Unadjusted survival of trial- and real-world patients.  Log-rank test comparison of unadjusted overall survival of patients treated in postapproval 
clinical trials with patients treated in the real-world. mo, months; CI, Confidence interval; OS, overall survival.
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can then be confirmed by randomized controlled trials. 
An example of supporting evidence from DMTR data 
on advanced melanoma patients treated with first-line 
targeted therapy with high LDH showed subsequent 
immunotherapy could lead to long-term survival if nor-
malization of LDH was reached [22]. This information is 
easily obtained with the use of a registry including real-
world practices.
Second, the choice for a data source depends on the avail-
ability of a high-quality registry and available data, or the 
resources to initiate postapproval clinical trials. In the 
case of the treatment with targeted therapies in patients 
with brain metastases, the intracranial response was used 
as a surrogate endpoint to assess effectiveness in these 
patients. An intracranial response in these patients, reg-
ulators argued, would lead to a clinical benefit, meaning 
treatment of these patients would be justified. Because 
the intracranial response is not registered in the DMTR, 
the core data set should have been expanded to match 
regulatory needs. The addition of such a data key point 
in a registry would in general require less effort than con-
ducting new postapproval studies.
Third, the choice depends on the patient population in 
question. Registries are a better data source when the 
remaining questions concern patients rarely included in 
phase III trials, such as the elderly or children. Registries 
can include rare patient populations over a longer period 
of time, leading to more data. This was the case when 
the Pediatric Committee of the EMA requested addi-
tional safety information in pediatric patients treated 
with ipilimumab [23]. The DMTR was chosen as a data 
source for these data because the number of children 
with advanced melanoma is limited. For this patient 
Fig. 3
Hazard ratios of a multivariable Cox proportional hazard model of advanced melanoma patients with brain metastases treated in postapproval 
clinical trials and the real world. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
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population, conducting a postapproval trial would be very 
challenging.
Broader perspective
Setting up or expanding disease-specific registries for 
postapproval evidence requires criteria sets. Registries 
come with a registration burden for caregivers and, there-
fore, the data set should be minimalized, including only 
the data points most important for the multiple stake-
holders (not only regulators but also caregivers, patients, 
HTAs, insurers and pharmaceutical companies). Such 
concision would reduce the registration burden. To use 
registry data to evaluate medicines, it also needs to be 
systemically collected, using criteria similar to those 
used in trials. This means data should also be noted 
concisely in electronic patient records or that key data 
points should be automatically filled. Using registries in 
this way to gather postapproval data on medicines will 
possibly be more effective than setting up and conduct-
ing (multiple) trials, which may have a longer lead-time. 
In a study including 600 nonrequired postapproval trials, 
the median duration of these trials was 37 (22–57) months 
[24]. The median duration of trials on cancer or hematol-
ogy (n = 437) was 43 (29–66) months. Of 204 completed 
or terminated postapproval trials, the duration from com-
pletion to reporting was 16 (13–25) months. This research 
[24] also showed 32% of the postapproval trials did not 
report results within 35 months after trial completion. 
The speed of data collection and gathering depends on 
the research question and the availability of informa-
tion in a registry. Delays affect patient care but can be 
addressed by registries from which outcomes could even-
tually be generated and reported more quickly if the data 
are already available.
Conclusion
High-quality population-based registries could be a com-
plementary data source to postapproval clinical trials to 
establish information on clinical outcomes in specific 
subpopulations with advanced melanoma after market 
authorization. Disease registries are more representative 
for the real-world population than patients treated in 
postapproval clinical trials, leading to improved under-
standing of the effectiveness of medicines in the real 
world. Postapproval data from registries can support reg-
ulatory decisions for remaining questions on new medi-
cines instead of postapproval studies.
Fig. 4
Overall survival of matched advanced melanoma patients with brain metastases treated in targeted therapy postapproval clinical trials and the 
real-world after propensity score matching.
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